Which drugs are most likely to be approved in Mixed Pain (Nociceptive Pain/Neuropathic Pain)?

Mixed Pain (Nociceptive Pain/Neuropathic Pain) disease is an indication for drug development with over 270 pipeline drugs currently active according to GlobalData.

Biopharma companies, BARDA call for more clarity on FDA’s new platform tech proposal

Following the FDA’s May release of long-awaited draft guidance explaining how companies can win designations for certain cell and gene therapy “platform” technologies, companies like

August 28, 2024

AstraZeneca posts 81% rise in FY 2023 profit after tax

Share this article AstraZeneca declared a stable full-year dividend per share of $2.90 for FY 2023. Credit: Tada Images / Shutterstock.com. AstraZeneca has reported a

February 9, 2024

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous 09.11.2023 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

November 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.